I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| hepatocyte | 6 studies | 85% ± 18% | |
| cholangiocyte | 4 studies | 54% ± 30% | |
| endothelial cell of sinusoid | 4 studies | 34% ± 16% | |
| hepatic stellate cell | 3 studies | 62% ± 24% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| hepatocyte | 6 studies | 85% ± 18% | |
| cholangiocyte | 4 studies | 54% ± 30% | |
| endothelial cell of sinusoid | 4 studies | 34% ± 16% | |
| hepatic stellate cell | 3 studies | 62% ± 24% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| liver | 4 studies | 63% ± 13% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 585950.40 | 226 / 226 | 97% | 3933.96 | 392 / 406 |
| lung | 90% | 3449.82 | 520 / 578 | 32% | 215.53 | 370 / 1155 |
| adrenal gland | 90% | 2627.97 | 233 / 258 | 7% | 44.98 | 16 / 230 |
| pancreas | 77% | 844.40 | 254 / 328 | 17% | 14.12 | 30 / 178 |
| stomach | 79% | 468.00 | 283 / 359 | 2% | 1.96 | 5 / 286 |
| kidney | 66% | 573.00 | 59 / 89 | 13% | 62.24 | 117 / 901 |
| ovary | 63% | 102.63 | 113 / 180 | 0% | 0 | 0 / 430 |
| bladder | 43% | 39.14 | 9 / 21 | 3% | 15.04 | 15 / 504 |
| spleen | 46% | 952.06 | 110 / 241 | 0% | 0 | 0 / 0 |
| breast | 37% | 75.55 | 169 / 459 | 3% | 15.32 | 30 / 1118 |
| uterus | 38% | 36.82 | 65 / 170 | 1% | 1.04 | 5 / 459 |
| peripheral blood | 38% | 347.70 | 350 / 929 | 0% | 0 | 0 / 0 |
| esophagus | 31% | 38.40 | 455 / 1445 | 4% | 8.72 | 7 / 183 |
| prostate | 31% | 26.55 | 76 / 245 | 0% | 0 | 0 / 502 |
| intestine | 29% | 34.32 | 279 / 966 | 2% | 19.56 | 9 / 527 |
| thymus | 30% | 29.72 | 195 / 653 | 0% | 0 | 0 / 605 |
| blood vessel | 24% | 23.83 | 315 / 1335 | 0% | 0 | 0 / 0 |
| heart | 24% | 34.26 | 203 / 861 | 0% | 0 | 0 / 0 |
| adipose | 22% | 95.42 | 270 / 1204 | 0% | 0 | 0 / 0 |
| skin | 21% | 28.98 | 381 / 1809 | 0% | 0.12 | 1 / 472 |
| muscle | 18% | 16.55 | 141 / 803 | 0% | 0 | 0 / 0 |
| brain | 15% | 11.76 | 399 / 2642 | 0% | 0 | 0 / 705 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_2000352 | Biological process | negative regulation of endothelial cell apoptotic process |
| GO_0072378 | Biological process | blood coagulation, fibrin clot formation |
| GO_0070527 | Biological process | platelet aggregation |
| GO_0007160 | Biological process | cell-matrix adhesion |
| GO_0045907 | Biological process | positive regulation of vasoconstriction |
| GO_0071347 | Biological process | cellular response to interleukin-1 |
| GO_0036345 | Biological process | platelet maturation |
| GO_0090277 | Biological process | positive regulation of peptide hormone secretion |
| GO_0042730 | Biological process | fibrinolysis |
| GO_0065003 | Biological process | protein-containing complex assembly |
| GO_0050714 | Biological process | positive regulation of protein secretion |
| GO_0051258 | Biological process | protein polymerization |
| GO_0034116 | Biological process | positive regulation of heterotypic cell-cell adhesion |
| GO_1900026 | Biological process | positive regulation of substrate adhesion-dependent cell spreading |
| GO_1902042 | Biological process | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors |
| GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
| GO_0051592 | Biological process | response to calcium ion |
| GO_0031639 | Biological process | plasminogen activation |
| GO_0045921 | Biological process | positive regulation of exocytosis |
| GO_0071354 | Biological process | cellular response to interleukin-6 |
| GO_0009306 | Biological process | protein secretion |
| GO_0005615 | Cellular component | extracellular space |
| GO_0031091 | Cellular component | platelet alpha granule |
| GO_0009897 | Cellular component | external side of plasma membrane |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0062023 | Cellular component | collagen-containing extracellular matrix |
| GO_0072562 | Cellular component | blood microparticle |
| GO_0009986 | Cellular component | cell surface |
| GO_0005788 | Cellular component | endoplasmic reticulum lumen |
| GO_0031093 | Cellular component | platelet alpha granule lumen |
| GO_0005577 | Cellular component | fibrinogen complex |
| GO_0005201 | Molecular function | extracellular matrix structural constituent |
| GO_0005102 | Molecular function | signaling receptor binding |
| GO_0042802 | Molecular function | identical protein binding |
| GO_0005198 | Molecular function | structural molecule activity |
| GO_0046872 | Molecular function | metal ion binding |
| GO_0050839 | Molecular function | cell adhesion molecule binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | FGG |
| Protein name | Fibrinogen gamma chain |
| Synonyms | PRO2061 |
| Description | FUNCTION: Together with fibrinogen alpha (FGA) and fibrinogen beta (FGB), polymerizes to form an insoluble fibrin matrix. Has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the antibacterial immune response via both innate and T-cell mediated pathways. . |
| Accessions | ENST00000405164.5 C9JU00 C9JPQ9 ENST00000407946.5 C9JEU5 ENST00000393846.6 P02679 ENST00000443553.5 ENST00000404648.7 [P02679-2] C9JC84 ENST00000336098.8 [P02679-1] |
